We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Altimmune Inc | NASDAQ:ALT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.17 | -2.30% | 7.22 | 7.20 | 7.33 | 7.48 | 7.20 | 7.41 | 1,715,778 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
| |||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number including area code: (
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On September 28, 2023, Altimmune, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”). As of August 11, 2023, the record date for the 2023 Annual Meeting, there were 52,686,426 shares of the Company’s common stock outstanding and entitled to vote at the 2023 Annual Meeting. A total of 34,561,978 shares of common stock were present or represented by proxy at the 2023 Annual Meeting, representing 65.6% of the issued and outstanding shares entitled to vote at the meeting, representing a quorum. The proposals voted upon and the final results of the vote were as follows:
Proposal No. 1: Election of Directors. The results were as follows:
| Broker | |||||
Director | For | Withhold | Non-Votes | |||
Mitchel Sayare, Ph.D., Chairman | 21,844,990 |
| 316,470 |
| 12,400,518 | |
Vipin K. Garg, Ph.D. | 21,885,151 |
| 276,309 |
| 12,400,518 | |
David J. Drutz, M.D. | 19,880,376 |
| 2,281,084 |
| 12,400,518 | |
John M. Gill | 21,588,792 |
| 572,668 |
| 12,400,518 | |
Philip L. Hodges | 21,810,125 |
| 351,335 |
| 12,400,518 | |
Diane Jorkasky, M.D. | 21,824,133 |
| 337,327 |
| 12,400,518 | |
Wayne Pisano | 19,385,875 |
| 2,775,585 |
| 12,400,518 | |
Klaus O. Schafer, M.D., MPH |
| 21,823,016 |
| 338,444 |
| 12,400,518 |
Catherine Sohn, Pharm D |
| 21,912,287 |
| 249,173 |
| 12,400,518 |
Proposal No. 2: Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. The results were as follows:
For | Against | Abstain | ||
34,318,768 | 153,149 |
| 90,061 |
Proposal No. 3: Advisory vote on the Compensation of the Company’s named executive officers as disclosed in the Proxy Statement pursuant to the SEC’s compensation rules (referred to as the “say-on-pay” proposal). The results were as follows:
For | Against | Abstain | Broker Non-Votes | |||
16,834,432 | 5,221,648 | 105,380 |
| 12,400,518 |
Proposal No. 4: Advisory vote on the frequency with which the Company will hold a non-binding, advisory vote on the compensation of its named executive officers as disclosed in the Proxy Statement pursuant to the SEC’s compensation rules (referred to as the “frequency of say-on-pay” proposal). The results were as follows:
1 Year | 2 Years | 3 Years | Abstain | Broker Non-Votes | ||||
21,595,590 | 80,595 |
| 352,096 |
| 133,179 |
| 12,400,518 |
Based on the votes set forth above, the Company’s stockholders approved, on a non-binding, advisory basis, a frequency of One Year for the non-binding, advisory vote on the compensation of the Company’s named executive officers. The Board of Directors considered these voting results and other factors, and has determined that the Company will hold future advisory votes on its executive compensation on an annual basis.
Proposal No. 5: Vote to authorize the adjournment of the 2023 Annual Meeting to enable the Board of Directors to solicit additional proxies. The results were as follows:
For | Against | Abstain | ||
27,712,554 | 6,744,992 |
| 104,432 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ALTIMMUNE, INC. | |||
By: |
| /s/ Richard Eisenstadt | |
| Name: Richard Eisenstadt | ||
| Title: Chief Financial Officer |
Dated: September 28, 2023
Document and Entity Information |
Sep. 28, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Sep. 28, 2023 |
Securities Act File Number | 001-32587 |
Entity Registrant Name | ALTIMMUNE, INC. |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 20-2726770 |
Entity Address, State or Province | MD |
Entity Address, Address Line One | 910 Clopper Road |
Entity Address, Address Line Two | Suite 201S |
Entity Address, City or Town | Gaithersburg |
Entity Address, Postal Zip Code | 20878 |
City Area Code | 240 |
Local Phone Number | 654-1450 |
Title of 12(b) Security | Common stock, par value $0.0001 per share |
Trading Symbol | ALT |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001326190 |
Amendment Flag | false |
Pre-commencement Issuer Tender Offer | false |
Pre-commencement Tender Offer | false |
Soliciting Material | false |
Written Communications | false |
N-2 |
Sep. 28, 2023 |
---|---|
Cover [Abstract] | |
Entity Central Index Key | 0001326190 |
Amendment Flag | false |
Securities Act File Number | 001-32587 |
Document Type | 8-K |
Entity Registrant Name | ALTIMMUNE, INC. |
Entity Address, Address Line One | 910 Clopper Road |
Entity Address, Address Line Two | Suite 201S |
Entity Address, City or Town | Gaithersburg |
Entity Address, State or Province | MD |
Entity Address, Postal Zip Code | 20878 |
City Area Code | 240 |
Local Phone Number | 654-1450 |
Entity Emerging Growth Company | false |
1 Year Altimmune Chart |
1 Month Altimmune Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions